Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0013395 (dyspepsia)
 4,879 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effects of therapeutic acupuncture on gastric acid secretion on pain relief in chronic duodenal ulcer patients were studied. Ten adult Nigerian patients with clinical, endoscopic as well as radiological evidence of duodenal ulcer constituted the "Ulcer Group." Four other patients who gave history of dyspepsia formed the "Dyspeptic Group." Pentagastrin stimulation test was performed on all subjects pre- and post-acupuncture therapy. The classical Chinese acupuncture loci were employed. The mean Basal Acid Output (BAO) in the duodenal ulcer group was markedly reduced from 4.04 +/- 1.01 mMols/hour to 1.05 +/- 2.5 mMols/hour. The mean Maximal Acid Output (MAO) was lowered from 34.72 +/- 13.81 mMols/hour to 15.34 +/- 4.01 mMols/hour. The difference was statistically significant (P less than 0.001). It is more probable, therefore, that the relief of pain is attributable to the therapeutic inhibition of gastric hyperacidity in our patients. Thus, though pain relief has been previously demonstrated in response to acupuncture, the results of this investigation have gone further to show that acupunture achieves symptomatic relief through therapeutic gastric depression in duodenal ulcer patients.
 ...
PMID:Acupuncture and gastric acid studies. 4 32

A questionnaire has been completed by 99 patients referred for investigation of symptoms after gastric operations. The replies were analysed in an attempt to distinguish patients with a recurrent peptic ulcer from those with no recurrent ulcer. All cases were investigated by barium meal, endoscopy, and oral cholecystography. All recurrent ulcers were confirmed by reoperation and patients with gastric carcinoma, gallstones, or symptomatic hiatus hernia were excluded. The study was retrospective in 40 patients in whom the diagnosis was already confirmed when the questionnaire was analysed and prospective in 59 in whom the diagnosis was originally unknown. The replies were analysed with (a) a small computer using Bayes' theorem, (b) weighted tables, and (c) a discriminant analysis. The computer prediction of the prospective data was 85% accurate. The results of simpler methods were almost as good as the computer prediction, and questions related only to the severity of pain and vomiting accurately distinguished recurrent ulcer from other causes of dyspepsia in 81% of patients.
 ...
PMID:A symptomatic discriminant to identify recurrent ulcer in patients with dysperpsia after gastric surgery. 5 52

The efficacy of flufenamic acid (3 times/day in 200 mg doses) was tested in a double-blind crossover study, using 44 primary dysmenorrheic patients. After 3 months of use, flufenamic relieved symptoms in most patients. Associated gastrointestinal symptoms were relieved in 66% and 52% (for vomiting and diarrhea, respectively), and 28% of patients experienced cessation of pain symptoms. 4 cases of drug-induced side effects were reported: dizziness and mild dyspepsia.
 ...
PMID:Flufenamic acid in treatment of primary spasmodic dysmenorrhoea. A double-blind crossover study. 7 92

A group of 85 patients suffering from non-articular rheumatic disorders was studied in an open trial of naproxen sodium in general practice. Patients were assessed and then treated for 7 days with naproxen sodium at a dosage of 275 mg 3 or 4-times daily depending on the severity of pain. Patients were asked to keep a daily record of symptoms and were re-assessed by the doctor after 7 days and, in some cases, after 14 days. Pain and limitation of movement were the predominant symptoms at admission. Patients' daily records showed statistically significant reductions in pain from Day 1 and significant reductions of limitation of movement from Day 2 of the study. At the 7-day follow-up, 27 were cured, 35 improved, 19 not changed or worse, and 4 were not assessed. Thirty patients were given a second weeks' therapy and at the end of this period 24 were cured or improved. Indigestion was the most common side-effect, but only 1 patient withdrew from the trial because of this. One patient developed a rash and was withdrawn from the trial. Both patients were taking the lower dose.
 ...
PMID:A study of non-articular rheumatic disorders and their response to treatment with naproxen sodium. 31 74

A single-blind, between-patient comparative study was carried out in general practice to assess the effectiveness of antacid plus antispasmodic combination tablets (240 mg dried aluminium hydroxide B.P., 144 mg magnesium hydroxide B.P.C., and 5 mg dicyclomine hydrochloride B.P.) and aluminium hydroxide B.P. tablets (500 mg) in the management of chronic dyspepsia. Twenty patients received the combination tablets and 17 the single antacid tablets. They were instructed to chew 2 tablets 3 or 4-times daily and an additional 2 tablets at night if necessary. Patients were assessed initially, and then at 2 and 4 weeks. Both preparations were effective in controlling dyspeptic symptoms. Heartburn and nausea showed an early, significantly greater (p less than 0.05) response to the combined tablet, as did night pain after 4 weeks. Tablet intake of both preparations averaged out at just under 7 tablets per day.
 ...
PMID:A comparison of an antacid plus antispasmodic combination and aluminium hydroxide in dyspepsia. 34 Jan 40

Following 3x200 mg Tagament (cymetidine SK & F) tablets at meals and 2 in the evening (5 per day) for an average of 31 days, complete endoscopic cure was obtained after 29 days (duodenal patients) and 35 days (gastric patients) in 26/27 subjects with slow healing histories (17 with duodenal and 10 with gastric ulcer). Rapid regression of pain and dyspepsia was observed form the outset and there was a marked reduction in the consumption of antacid preparation. Its marked efficacy and good tolerance make Tagamet a drug of choice in the treatment of peptic, duodenal and gastric ulcers.
 ...
PMID:[Preliminary results of treatment with Tagamet (cimetidine SK and F) in gastric and duodenal ulcers]. 35 35

A double-blind, cross-over comparison of Naprosyn (naproxen) 750 mg daily and Butacote (enteric-coated phenylbutazone) 300 mg daily was carried out in a multi-centre trial. Twenty-five patients, mostly male and under 40 years of age, were entered. After a 2-week period in which any existing anti-inflammatory drugs were tailed off, patients were entered into the trial and treated for 1 month with each drug. Patients were assessed at 4-weekly intervals. Both drugs significantly reduced morning stiffness. Morning pain and discomfort and wall-tragus distance were also significantly reduced by both drugs during the trial. Results of the Schober test showed improvement during both treatment periods. There were no overall statistically significant differences between the effects of the 2 drugs on objective parameters. However, overall subjective assessment of symptoms showed a greater improvement on Butacote. Treatment preferences by physician and subjective assessment by the patient both favoured Butacote but the difference between the 2 drugs was not statistically significant. Side effects were mostly of a minor nature. One patient had to discontinue the trial, due to indigestion while taking Butacote.
 ...
PMID:A comparative study of Butacote and Naprosyn in ankylosing spondylitis. 36 71

A double-blind trial compared diclofenac with placebo in 44 outpatients. On from each group dropped out with dyspepsia, and one (placebo group) with ineffective treatment. Twenty completers received diclofenac. Dosage was one tablet (25 mg diclofenac) three times daily during the first week. In the second (final) week, most patients had four or six tablets. Diclofenac had significantly greater effect on pain, grip, morning stiffness, joint tenderness and swelling, and in comparison to previous treatments, even though the placebo group required significantly more rescue anaglesic. A few patients in each group had slight dyspepsia. One in the active and six in the placebo group complained of minor central nervous system symptoms. There were no serious side-effects. Haematological, biochemical and urinary analyses showed no clinically important changes. It is concluded that, in the short term, diclofenac (Voltarol) is effective in relieving the symptoms of inflammatory polyarthritis. It is well tolerated as placebo medication, and had no detrimental haematological or biochemical effects.
 ...
PMID:Diclofenac (Voltarol) in rheumatoid arthritis: a report of a double-blind trial. 39 80

73 patients with definite active rheumatoid arthritis were treated with naproxen, 250 mg b.i.d. One month after the start of therapy the patients were examined as to following parameters: spontaneous pain and pain on movement, duration of morning stiffness, fatigue, grip strength, functional joint index, ESR and consumption of analgesics. On statistical analysis a significant improvement of all the parameters, with the exception of ESR was shown, 52 of the 73 patients were very satisfied resp. satisfied with the treatment, whereas the physician evaluated the therapeutic results as very good to good in 49 of the cases. In 50 of the patients the therapy with naproxen, 250 mg b.i.d., was continued for two more months. In most of these cases it was possible to achieve an additional improvement in the parameters evaluated. Unwanted side effects occurred in 7 patients, of which in 4 the treatment had to be discontinued (in two cases because of dyspepsia and once each because of an angioneurotic edema and a recurrence of a peptic ulcer, respectively). The three patients in whose cases therapy was continued suffered from mild gastrointestinal disturbances.
 ...
PMID:[Treatment of progressive chronic polyarthritis with a non-steroidal antirheumatic agent with a long half-life]. 44 68

Sixty-one cases of the Zollinger-Ellison syndrome, encountered over a 2-year period, have been treated with cimetidine, half of them for over 1 year. Two-thirds of the patients responded to 300 mg of the drug every 6 hr by mouth. Others required up to 600 mg every 6 hr. In adequate doses the drug was highly effective: it controlled pain and dyspepsia, restored weight, abolished diarrhea, and allowed healing of ulcers and other inflammatory conditions. Missed or reduced doses led to rapid return of symptoms. Progression of the basic neoplastic process, with associated secretory drive, was unimpeded. Patient acceptance of the drug was 100 percent, and apart from minor transient abnormalities, gynecomastia (5 cases) and liver dysfunction (3 cases), which resolved while treatment continued, no serious adverse effects were seen. Of 61 patients 48 are still on the drug, 3 who were well controlled were treated surgically, 5 died for reasons unrelated to therapy, and 5 had significant problems. The drug provides an alternative to total gastrectomy and can be recommended with confidence for the suitably selected patients. The drug was also beneficial in some cases of the short bowel syndrome, systemic mastocytosis, and endogenous hyperhistaminemia due to leukemia.
 ...
PMID:Report on the United States experience with cimetidine in Zollinger-Ellision syndrome and other hypersecretory states. 62 Sep 13


1 2 3 4 5 6 7 8 9 10 Next >>